Table 6 Short-term results of phase II and of retrospective available studies
|
Author ( a Study) | N. of patients | Stage | Radiotherapy | Compliance RT-CT | pCR | Tox ≥ 3 | Post-op morbidity |
|---|---|---|---|---|---|---|---|
|
De Ridder et al. [24] (Phase II) | 24/13 |
T3-T4 MRF+ |
46Gy/23fr/2 SIB 55.2Gy/23fr/2.4Gyfr | 100% -noCT | 14% | 4.2% | 8% |
|
Li et al. [25] (Phase II) | 63 |
T3-T4 N+ |
41.8Gy/22fr/1.9 SIB 50.6Gy/22fr/2.3Gyfr | 100% –100% | 31% | 14% | 7% |
|
Hernando et al. [26] (Retrospective) | 74 |
T2-T4 N+ |
45Gy/25fr/1.8 SIB 57.5Gy/25fr/2.3Gyfr | 99% – 99% | 31% | 17.6% | 7% |
|
Zhu et al. [27] (Phase II) | 78 |
T3-T4 N0/N+ |
50Gy/25fr/2 SIB 55Gy/25fr/2.2Gyfr | 100% – 62% | 24% | 14% | 17% |
|
Wang et al. [28] (Retrospective) | 260 |
T3-T4- N0/N+ |
41.8Gy/22fr/1.9 SIB 50.6Gy/22fr/2.3Gyfr | 99% – 99% | 18.5% | 6% | 23% |
|
bArbea et al. [29] (Phase II) | 100 |
T3-T4 N+ |
47.5Gy/19fr/2.5 and
47.5Gy/20fr/2.4Gyfr | 97% – 80% | 13% | 25% | 7% |
| Our experience | 76 |
T3-T4 N0/N+ |
45 Gy/25fr/1.8 SIB 52.5–57.Gy/25fr 2.1–2.3Gyfr | 97.4% – 84% | 22% | 10.5% | 18% |